Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRUIT: Tislelizumab + Fruquintinib + SBRT in Advanced Colorectal Cancer
NCT04924179Phase 2Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jun 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in colorectal cancer (CRC), sponsored by Huazhong University of Science and Technology. Primary endpoint: Progression-free survival at 16 months. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04924179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924179.